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Objective: Increasing plasma levels and activity of dipeptidyl peptidase-4 (DPP4 or CD26) are associated with rapid progression of metabolic
syndrome to overt type 2 diabetes mellitus (T2DM). While DPP4 inhibitors are increasingly used as anti-hyperglycemic agents, the reason for the
increase in plasma DPP4 activity in T2DM patients remains elusive.
Methods: We looked into the source of plasma DPP4 activity in a cohort of 135 treatment naive nonobese (BMI < 30) T2DM patients. A wide
array of ex vivo, in vitro, and in silico methods were employed to study enzyme activity, gene expression, subcellular localization, protease
identiﬁcation, surface expression, and proteineprotein interactions.
Results: We show that circulating immune cells, particularly CD4þ T cells, served as an important source for the increase in plasma DPP4
activity in T2DM. Moreover, we found kallikrein-related peptidase 5 (KLK5) as the enzyme responsible for cleaving DPP4 from the cell surface by
directly interacting with the extracellular loop. Expression and secretion of KLK5 is induced in CD4þ T cells of T2DM patients. In addition, KLK5
shed DPP4 from circulating CD4þ T helper (Th)17 cells and shed it into the plasma of T2DM patients. Similar cleavage and shedding activities
were not seen in controls.
Conclusions: Our study provides mechanistic insights into the molecular interaction between KLK5 and DPP4 as well as CD4þ T cell derived
KLK5 mediated enzymatic cleavage of DPP4 from cell surface. Thus, our study uncovers a hitherto unknown cellular source and mechanism
behind enhanced plasma DPP4 activity in T2DM.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords DPP4; KLK5; PBMC; T2DM; Th17 cells1. INTRODUCTION
Gut-derived incretin hormones glucagon-like peptide (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) directly activate
insulin secretion via binding to their distinct receptors on the
pancreatic islet b-cells [1]. Blunted ﬁrst phase insulin secretion,
attributed mainly to GLP-1 deﬁciency but also partly to GIP resistance,
is intimately linked to T2DM [1]. The ubiquitously expressed negative
regulator of incretin hormones, DPP4 exists either as a single pass type
II transmembrane protein or as a shedded soluble form of serine
protease that hydrolyzes proline or alanine from the N-terminus of
different polypeptides including incretin hormones [1,2]. Plasma levels
and activity of DPP4 have been found to be associated with progres-
sion of metabolic syndrome [3]. Nevertheless, the reason behind this
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T2DM, insulin resistance and associated clinical outcomes of meta-
bolic syndrome are causally related to low grade chronic systemic
inﬂammation, or metaﬂammation, in metabolically active tissues [4].
Recruitment and activation of plethora of immune cells, such as
macrophage [5e7] conventional dendritic cells [5,6], plasmacytoid
dendritic cells [8], T cells [9], and neutrophils [10], in the metabolically
active tissues including pancreas, adipose, and liver [7,8,11,12] is well
documented in patients as well as in animal models of the disease.
Immune cell homing in speciﬁc organs leads to obesity associated
deregulated metabolic outcome [7] and inﬂammatory cytokines
secreted from immune cell regulate metabolic homeostasis [13] and
insulin resistance [14]. Interestingly, DPP4 is expressed in a subset of
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Table 1 e Subject characteristics and biochemical parameters.
Subjects Control T2DM p-value
control vs
T2DM
N (M/F) 78 (50/28) 135 (91/56)
Age (years) 44.6  9.63 47.2  10.9 0.14
BMI (kg/m2) 23.43  2.3 23.24  2.34 0.621
Waist circumference (cm) 87.75  9.52 90.24  9.27 0.268
Hip circumference (cm) 93.23  9.02 95.15  7.8 0.315
Neck girth (cm) 33.5  3.17 34.05  3.61 0.508
%FAT(skin fold) 32.98  6.8 31.55  8.47 0.396
Fasting blood glucose
(mg/dl)
95.22  8.25 165.15  65.23 <0.001
Post-prandial blood
glucose (mg/dl)
131.78  22.82 311.35  106.07 <0.001
HbA1c (%) 5.35  0.37 8.26  2.54 <0.001
Triglyceride (mg/dl) 132.72  72.77 156.93  86.7 0.017
Total cholesterol (mg/dl) 183.24  36.69 195.14  50 0.121
HDL cholesterol (mg/dl) 46.62  11.59 43.04  12.11 0.027
LDL cholesterol (mg/dl) 108.81  29.26 117.32  35.61 0.085
VLDL cholesterol (mg/dl) 29.24  27.35 31.76  19.03 0.05
GGT 25.85  22.02 33.9  26.30 0.019
AST 23.92  17.92 29.33  36.40 0.752
ALT 21.09  24.08 25.22  38.42 0.619
Fasting insulin (mIU/ml) 7.81  5.71 9.33  11.45 0.314
HOMA-IR 1.84  1.37 3.61  4.34 0.004
HOMA-BETA 94.37  76.58 0.45  0.51 <0.001
Leptin (mg/ml) 9.2  12 5.015  4.886 0.133
GIP fasting (pg/ml) 122.56  77.58 97.5  38.88 0.12
30 min GIP (pg/ml) 347  98 371.72  140 0.492
GLP-1 fasting (pg/ml) 5.35  1.5 6.28  2.58 0.112
30 min GLP-1 (pg/ml) 13.77  9.64 11.3  8.6 0.421
Plasma DPP4 activity
(nmol/min/ml)
16  18.29 24.4  21.31 <0.001
Plasma DPP4 levels
(ng/ml)
39.30  12.28 48.54  21.13 <0.05
Original Articlebound as well as soluble DPP4 have been described as co-stimulatory
molecules for T cell activation often via interactions with adenosine
deaminase [15]. Moreover, it was shown that the DPP4 level in T cells
was increased in T2DM patients and linked with long term glycemic
control [16]. Of note here, DPP4 expression is maximum in IL-17
producing CD4þ T cells (Th17 cells), which are one of the major
participants of inﬂammation in obesity associated T2DM [17].
In the present study, we tested the hypothesis that circulating immune
cells, speciﬁcally the Th17 cells, may be the major source of plasma
DPP4 abundance and activity in T2DM patients and explored the
possible mechanisms that leads to release of soluble DPP4 in plasma
of these patients.
2. MATERIALS AND METHODS
2.1. Patient recruitment
A total of 213 individuals were recruited for baseline experiment from
Institute of Postgraduate Medical Education & Research (IPGME&R)
following the American Diabetes Association (ADA) criteria [18]. Among
them, 135 were treatment-naïve type 2 diabetes patients, and 78 were
healthy, age-matched controls. All subjects gave informed consent, and
research was approved by the ethical committees of IPGME&R hospital
and CSIR-IICB. After overnight fasting, blood samples were drawn in
EDTA tubes to measure glucose and glycated hemoglobin (HbA1c), total
cholesterol (TC), total triglyceride (TG), high density lipoprotein (HDL), low
density lipoprotein (LDL), insulin, leptin, GIP, GLP-1, DPP4 concentra-
tions, and plasma DPP4 activity. Blood samples were also drawn 30 min
after a 75 g oral glucose load. Plasma samples were obtained after
centrifugation and stored at 80 C until analysis. Homeostatic model
assessment (HOMA) was utilized for quantiﬁcation of insulin resistance
(HOMA-IR) andb cell function (HOMA-b). Anthropometricmeasurements
such as weight, height, waist and hip circumference, neck girth, and skin
fold thickness at four different sites (abdomen, suprailiac, triceps, and
thigh) was measured using Herpenden Skin fold caliper (Baty Interna-
tional Ltd). Skin fold measurements were taken for total body fat per-
centage calculation. Clinical and biochemical parameters of 213 subjects
are shown in Table 1. Additionally, in a subset of randomly select cases
(41 treatment naïve T2DM and 48 control subjects), an additional 5 ml of
blood samples were taken for peripheral blood mononuclear cells
(PBMC) isolation and for other downstream experiments.
2.2. Peripheral blood mononuclear cell (PBMC) culture
PBMCs were isolated using HiSep LSM 1077 (Himedia Laboratories).
Brieﬂy, EDTA blood was diluted 1:1 with sterile PBS and layered on
HiSep LSM1077. Sampleswere centrifuged for 30min at 500gwithout
applying a brake. Comparable viability of PBMCs in control and T2DM
patients was ﬂow cytometrically determined by AnnexinV apoptosis kit
(eBiosciences) (Supplementary Figure 1). The PBMC interface was
carefully removed and washed twice with PBS. CD4þ T cells were pu-
riﬁed from PBMC by standard MACS protocol (MiltenyiBiotec). Finally,
PBMC and CD4þ T cells were cultured in anti-CD3 (eBioscience) coated
plates treated with 2 mg/ml anti-CD28 antibodies (BD Pharmingen) in
10% FBS containing RPMImedia. For DPP4 and KLK5 secretion analyses,
culture supernatants were assayed for DPP4 and KLK5 levels by ELISA
(R&D Systems). To identify the speciﬁc proteolytic enzyme involved in
DPP4 shedding, 10 mMMMP inhibitor (GM 6001; Sigma) and 100 mg/ml
KLK inhibitor (aprotinin; Sigma) were used for 24 h and 16 h respectively.
2.3. DPP4 enzyme assay
DPP4 activity in plasma and in PBMC lysates was assayed as
described before [19]. Brieﬂy, DPP4 activity was determined as the1530 MOLECULAR METABOLISM 6 (2017) 1529e1539  2017The Authors. Published by Elsevier GmbH.rate of 7-amino-4-methylcoumarin (AMC) cleavage per minutes per ml
from the synthetic substrate H-glycyl-prolyl-AMC (Sigma). AMC ﬂuo-
rescence (excitation/emission e 380/460 nm) was measured in a
plate reader (Synergy H1 multi-mode microplate reader, Biotek).
2.4. Protease proﬁling
After 48 h culture of PBMC, supernatant from 8 different individuals
were pooled in a single tube and protease proﬁle was determined
using a protease array kit (R&D Systems).
2.5. Cells culture and transfection
Human DPP4 clone (Open Biosystems) and KLK5 clone (MyBioSource)
were subcloned with a C-terminal HA-tag into IRES vector and
pcDNA3.1/myc-His() B vector respectively. The MMP2 clone was
from Origene. HepG2 cells stably expressing HA-DPP4 were generated
by transfection followed by puromycin selection (2 mg/ml, InvivoGen).
Cells were washed with PBS and incubated with 150 nM human re-
combinant KLK5 (R&D Systems) for 4 h at 37 C. DPP4 cleavage was
analyzed in culture supernatants by ELISA (R&D Systems). In transient
co-transfection experiments, 2 mg of KLK5 plasmid and 200 ng of GFP
plasmid were used. A constitutive GFP-expressing vector served as a
transfection control. Membrane bound DPP4 expression was detected
at 40 h post-transfection.
2.6. Confocal microscopy
HepG2 cells stably expressing HA-DPP4 were grown in a confocal dish
and transfected with plasmids. CD4þ T cells were isolated, stimulated
with anti-CD3/CD28 antibodies and grown in polylysine coatedThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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confocal dishes. Cells were incubated with human recombinant KLK5
(150 nM) in PBS for 4 h at 37 C and ﬁxed with 4% paraformaldehyde
(Sigma) for 20 min, washed with PBS, and blocked in 6% goat serum
for 1 h. HA-DPP4 overexpressing HepG2 cells and CD4þ T Cells were
immunostained with rabbit anti-HA antibody (1:50; Cell Signaling) and
rabbit anti-human DPP4 mAb (1:100; Abcam) in 6% goat serum
overnight at 4 C, followed by incubation with FITC-conjugated goat
anti-rabbit and Alexa Fluor 546-conjugated goat anti-rabbit antibody
secondary antibody (1:1000; Life Technologies) for 1 h respectively.
Nuclei were stained with Hoechst 33342 (Thermoﬁsher Scientiﬁc) for
20 min. Cells were imaged with a Nikon A1R confocal imaging system
(Tokyo, Japan) and ﬂuorescence intensity in individual cells was
analyzed using Image J software.
2.7. Gene expression analysis
Total cellular RNA from PBMC was isolated using TRizol reagent (Life
Technologies, USA) and RNA concentration was measured by Nano-
Drop (Thermo Scientiﬁc). cDNA was synthesized from 1 mg RNA using
reverse transcription supermix (BioRad). Gene expression was deter-
mined by quantitative PCR (LightCycler 96 real time PCR, Roche) using
SYBR Green master mix (FastStart Universal SYBR Green Master,
Roche) and analyzed by DDCt method and normalized by 18S RNA.
The primer sequences are available upon request.
2.8. siRNA electroporation
Isolated CD4þ T cells were cultured for 1 h in complete medium at
37 C in CO2 incubator. Cells were carefully washed with PBS and
resuspended in electroporation buffer (RPMI media, 1 glutamine, 1
sodium pyruvate, no antibiotics or FBS). 100 ng/ml of siKLK5 in 150 ml
electroporation buffer containing cells were gently mixed and incu-
bated for 10 min at room temperature. Then, the mixture was trans-
ferred into 0.2 cm Biorad gene pulser XL cuvettes and electroporated
using 250 V and 950 uF capacitance pulse by Gene Pulser (Bio-Rad).
Then, cells were transferred to 200 ml complete RPMI medium in 96
well plates and incubated at 37 C in CO2 incubator for 3 days.
Knockdown was checked after 72 h by qPCR.
2.9. Flow cytometry assay
CD4þ T cells were isolated by standard MACS protocol (Miltenyi
Biotec). The enriched CD4þ T cells fraction were cultured overnight in
anti-CD3 (eBioscience) coated plates, treated with 2 mg/ml CD28
antibody (BD Pharmingen). Then, 1 mg/ml ionomycine (Sigma) and
10 ng/ml PMA (Sigma) were applied to the media for 2 h before adding
brefeldin. Finally, brefeldin was added during the last 4 h of culture.
Cells were then stained with following anti-human, ﬂuorophore tagged
antibodies: CD8 PerCP (eBioscience) and CD26 PE (eBioscience). To
assess phenotype of CD4þ T cells, the cells were permeabilized with
saponin and stained with anti-human IFNg-FITC (BD Bioscience) and
IL-17A-EF450 (eBioscience) antibodies. Cells were gated on lympho-
cytes though forward and side scatter and the doublets were excluded.
CD4 T cells (CD8 negative) were checked for the expression of IFNg
(FITC-H) and IL-17 (EF450). IFNg and IL-17 positive cells were denoted
as Th1 and Th17 cells respectively. Then expression of membrane
bound CD26 (PE) was checked on both of these populations. Cells were
analyzed on BD FACS Aria ﬂow cytometer. Gating strategies are shown
in Supplementary Figure 2AeC. For isolation of puriﬁed Th1 and Th17
cells, the CD4þ T cells were stained with anti-human CCR5-PE (R&D
Systems)/CXCR3-Bv421 (BD Biosciences) and CCR6-APC/CCR4 PerCP
(R&D Systems) antibodies respectively. The labeled cells were sorted
by MoFlo XDP cell sorter (Beckman Coulter). Gating strategies with
exclusion of doublets are shown in Supplementary Figure 2DeG.MOLECULAR METABOLISM 6 (2017) 1529e1539  2017TheAuthors. Published by ElsevierGmbH. This is an o
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DPP4 protein structure
The protein sequence of DPP4 was subjected to TMPred [20] TMHMM
[21] and HMMTop [22] servers and the consensus predicted 22 (re-
gion: V7 e L28) residues long region was selected as transmembrane
(TM) helix. The sequence (region: M1- T42) encompassing TM helix
and ﬂanking loop was subjected to Robetta server [23] for ab-initio
modeling and further validated by Errat [24] and Rampage [25] vali-
dation programs. The crystal structure of the extracellular domain of
DPP4 (PDB ID: 1N1M, region: S39 e P766) and the ab-initio model of
the N-terminal part were used to build a three-dimensional (3D) model
of full length DPP4 protein. Modeler v9.16 [26] was used to build the
models, and top models were ﬁltered based on the Modeler energy
parameters, MOLPDF, and DOPE scores. The stereo-chemical prop-
erties and the fold compatibility of the ﬁnal model were validated by
Rampage [25] Verify3D [27], and Errat [24] programs. The ﬁnal DPP4
model was inserted into a 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) bilayer (dimension: 100A  100A  45A),
and molecular dynamic (MD) simulation was carried out using Des-
mond [28] program for 100 ns (nanoseconds) at 300 K temperature.
The OPLS_2005 force ﬁeld parameters [29] were used for the simu-
lation. MD simulation trajectory ﬁles were analyzed by various analysis
programs of the Desmond package. Root mean square deviation
(RMSD) and root mean square ﬂuctuation (RMSF) plots suggest that
the overall structure does not deviate too much (<1 A), keeping a
lower level of ﬂuctuation for most of the regions of the protein
(Supplementary Figure 3A, B). The secondary structural content of the
initial structure remains stable throughout the length of the simulation
(Supplementary Figure 3C), whereas the overall structure became
slightly more compact (Supplementary Figure 3D). However, the en-
ergy of the system evolved favorably with the duration of the simulation
indicating better stability of the ﬁnal DPP4 structure (Supplementary
Figure 3E).
2.11. Molecular docking and MD simulation of DPP4eKLK5
docked complex
The stable DPP4 structure embedded in POPC bilayer obtained after
100 ns simulation was docked with the crystal structure of KLK5 (PDB
ID: 2PSY) using proteineprotein docking mode of PatchDock [30]
program. Residues 38e40 of DPP4 were considered to be important
for binding as the proteolytic cleavage by KLK5 active sites resides at
D38-S39-R40 region of DPP4. Hence, region 38e40 of DPP4 and the
known catalytic sites of KLK5 were used as seed regions for docking
experiment. Approximate interface area and DG of binding of the
docked complexes were calculated using the PDBePISA server [31].
The docking solutions were screened, and the best DPP4eKLK5
docked complex was identiﬁed based on interface area, DG of binding,
and critical inspection of favorable interactions between the two pro-
teins. The selected docked complex was energetically stable as min-
imal energy gain (1.5%) was obtained even after 100 ns of
simulation (Supplementary Figure 1F). The energy gain of the selected
complex is relatively lesser and/or comparable to that of known of
complexes (Supplementary Figure 1F).
2.12. Statistics
Statistical analysis was performed using GraphPad Prism 5 software
(La Jolla, CA, USA). Descriptive summary of the data has been done by
mean and standard deviation. Numerical variables have been
compared between groups by independent-samples t-test or Manne
Whitney U test as appropriate. Pearson’s correlation coefﬁcient ‘r’ or
Spearman’s rank correlation coefﬁcient rho (r) have been calculated topen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1531
Figure 1: PBMC is an important source of increased plasma DPP4 activity in T2DM patients. DPP4 activity in plasma and peripheral blood mononuclear cells (PBMC) of
treatment naïve type 2 diabetes (T2DM) patients and healthy control subjects. DPP4 expression in PBMC was measured and linear regression analysis was performed with
Spearman correlation. (AeC) Comparison of plasma (control n ¼ 78 & T2DM n ¼ 135) PBMC DPP4 activity (control n ¼ 46 & T2DM n ¼ 35) and PBMC DPP4 gene expression
(control n ¼ 49 & T2DM n ¼ 41). (DeG) Linear regression analysis of PBMC DPP4 activity with plasma DPP4 activity (D&F), and PBMC DPP4 activity and gene expression (E&G). (H,
I) PBMCs from control (n ¼ 22) and treatment naïve T2DM subjects (n ¼ 28) were cultured for 48 h and supernatant (H) as well as cellular DPP4 levels (I) were analyzed by ELISA.
Statistical analysis was performed by ManneWhitney U test and Student’s t test with Spearman correlation; *p < 0.05, ***p < 0.001.
Original Articleexplore association between variables. P-value less than 0.05
considered statistically signiﬁcant.
3. RESULTS
3.1. Plasma DPP4 activity is increased in non-obese T2DM
patients
To explore the source of plasma DPP4 in T2DM, we recruited 213
treatment naïve subjects (control, n ¼ 78; T2DM, n ¼ 135). The
clinical and biochemical characteristics of the cohort are shown in
Table 1. Pancreatic b-cell function represented by HOMA-b is impaired
while insulin resistance represented by HOMA-IR is increased in T2DM
patients. Of note, adiposity among the groups were equivalent as no
statistical differences seen in body mass index (BMI), neck girth and
plasma leptin levels. Thus, our T2DM cohort represented normoinsu-
linemic, hyperglycemic, non-obese (BMI < 30) subjects. Fasting
plasma DPP4 enzymatic activity was found to be signiﬁcantly
increased in T2DM (p < 0.001) populations from the control group
(Figure 1A), in line with previous reports [32]. DPP4 protein levels were1532 MOLECULAR METABOLISM 6 (2017) 1529e1539  2017The Authors. Published by Elsevier GmbH.also increased; however, we did not ﬁnd any difference in plasma
levels of GLP-1 or GIP either in fasting or 30 min after glucose ingestion
(Table 1).
3.2. PBMC is an important source for plasma DPP4 activity
To explore the validity of our hypothesis that immune cells circulating
in the peripheral blood may be the source of DPP4 abundance in
diabetes, we determined DPP4 activity and gene expression in PBMCs
isolated from the recruited individuals. Cell viability in the isolated
PBMCs in control and T2DM patients was comparable (Supplementary
Figure 1). In contrast to increased plasma DPP4 activity, we did not
detect any corresponding increase either in PBMC DPP4 activity
(Figure 1B) or in gene expression (Figure 1C) in the T2DM population.
However, DPP4 enzymatic activity in PBMC homogenate positively
correlated with both DPP4 gene expression (r ¼ 0.538, p ¼ 0.03;
Figure 1D) and plasma DPP4 activity (r¼ 0.549, p< 0.001; Figure 1E)
in the control population. In T2DM individuals, however, there was no
correlation between PBMC DPP4 expression and PBMC DPP4 enzy-
matic activity (Figure 1G). More interestingly, there was actually aThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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negative correlation between PBMC DPP4 activity and plasma DPP4
activity in T2DM (Figure 1F). These correlation studies indicated that, in
the control population, plasma DPP4 activity is contributed by PBMC
DPP4 levels and reversal of this correlation pointed to possible
sourcing of plasma DPP4 activity from cellular DPP4 in peripheral blood
in T2DM. To explore this possibility in vitro, we measured release of
DPP4 into the PBMC culture supernatant from control and T2DM pa-
tients. As shown in Figure 1H, DPP4 release into the PBMC culture
supernatants was signiﬁcantly enhanced in T2DM patients, compared
to controls, thus corroborating the correlation studies. However, we did
not ﬁnd any difference in DPP4 levels in the PBMC homogenate
(Figure 1I) suggesting that only a small fraction of total cellular DPP4 is
shed from PBMC.
3.3. KLK5 expression and secretion are enhanced from PBMC of
T2DM patients
The release of soluble DPP4 protein into PBMC culture supernatants
encouraged us to identify the proteases that may be differentially
enriched in or secreted from the PBMCs in T2DM patients and which
potentially could cleave off DPP4 from the immune cell surface. We
pooled PBMC supernatants from eight control subjects and eight T2DM
patients to check for the relative abundance of secreted proteases fromFigure 2: KLK5 is the proteolytic enzymes involved in the DPP4 shedding from PBM
proﬁle was performed. Spots for KLK5 are marked (A). Data are represented as relative pix
gene expression (control n ¼ 17 & T2DM n ¼ 20). (D) Plasma KLK5 levels (control n ¼
inhibitor (MMPi; control n ¼ 6 and T2DM n ¼ 9) and 100 mg/ml KLK inhibitor (KLKi; contro
measured by ELISA. Statistical analysis was calculated by ManneWhitney U test and sho
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www.molecularmetabolism.coma panel of 34 proteases. We found that serine protease KLK5 was
highly enriched in PBMC culture supernatants of T2DM patients
(Figure 2A,B). As expected, the presence of DPP4 in the PBMC su-
pernatants was also increased in T2DM (Figure 2A,B). Gene expression
of KLK5 in PBMC was also signiﬁcantly up regulated in T2DM
(Figure 2C). However, we did not ﬁnd any increase in plasma KLK5
levels in T2DM patients (Figure 2D). Next, to examine whether KLK
proteases are responsible for DPP4 shedding we used a broad spec-
trum KLK inhibitor aprotinin (KLKi). As shown in (Figure 2E), incubation
with KLKi markedly reduced DPP4 shedding from both control and
T2DM PBMCs while the broad spectrum MMP inhibitor GM 6001
(MMPi) had no such effect (Figure 2F). Thus, unlike adipose and
smooth muscle, in which DPP4 is cleaved by speciﬁc MMP [33], KLKs
serve as the protease for DPP4 shedding from circulatory immune
cells.
3.4. KLK5 cleaves DPP4 on the extracellular domain
To examine whether KLK5 could interact and cleave membrane bound
DPP4 on the cell surface, we ﬁrst adopted molecular modeling and
docking approaches. The validated model of the full length DPP4
protein embedded within POPC bilayer was stabilized using 100 ns
molecular dynamic simulation (Figure 3A). 3D structure of KLK5 (PDBC. (A, B) PBMC culture supernatants were pooled (n ¼ 8) and a human protease array
el density of signiﬁcantly altered proteases in T2DM (B). (C) Comparison of PBMC KLK5
29 & T2DM n ¼ 36). (E, F) PBMC was incubated for 24 h and 16 h with 10 mM MMP
l n ¼ 6 and T2DM n ¼ 12) respectively. DPP4 release in the culture supernatants were
wn as box plots; p**<0.01, ***p < 0.001.
pen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1533
Figure 3: KLK5 cleaves DPP4 from cell surface through direct interaction. (A) Model structure of the full length DPP4 protein where DPPIV_N domain is marked in purple,
Peptidase_S9 domain in green, and linker domain in orange, respectively. The transmembrane (TM) region is marked in blue, embedded in POPC bilayer. Initial (0th ns) and end
structure (100th ns) of the 100 ns molecular dynamics simulation. (B) Probable mode of docking of KLK5 (shown in pale blue) with the DPP4. Cleavage site of DPP4 (38DSR40) and
the catalytic triad (H57, D103 and S197) of KLK5 are shown in yellow and magenta, respectively. Other associated active sites of KLK5 are shown in chocolate brown. (C) Close up
version of the binding region where cleavage site of DPP4 (38DSR40) and the catalytic triad (H57, D103 and S197) of KLK5 are shown in yellow and magenta, respectively. (D)
Non-permeabilized HA-DPP4 expressing HepG2 cells were stained with anti-HA antibody (green) and Hoechst (blue) and visualized with ﬂuorescence confocal microscopy. Left
panel: Representative ﬁelds of control. Right panel: rKLK5 treated cells. Scale bar ¼ 20 mm. (E) Fluorescence intensity for 50 different cells across three ﬁelds was measured by
Image J software. (F) HepG2 cells expressing HA tagged DPP4 were treated with recombinant KLK5 for 4 h and culture supernatants were analyzed by DPP4 ELISA. (G)
Fluorescence confocal microscopy images of the stable HA-DPP4 expressing HepG2 cells co-transfected with KLK5 and GFP plasmids. A constitutive GFP-expressing vector served
as a transfection control. Membrane bound DPP4 expression was detected with anti-HA antibody (red) at 40 h post-transfection. Scale bar ¼ 20 mm. (H) Fluorescence intensity was
calculated of 40 different GFP positive and negative cells across three ﬁelds by Image J software. Data are shown as the mean  SD. Statistical analysis was performed by
Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001.
Original ArticleID: 2PSY) was docked onto the DPP4 model obtained after 100 ns
simulation. Most likely mode of interaction was selected based on
interface area (1335.5A2), DG of binding (8.4 kcal/mol) and critical
inspection of favorable interactions (5 probable hydrogen bond and 1
salt bridge interaction). Figure 3B shows the overall binding mode
whereas Figure 3C shows the structural proximities (5A) of critical
residues for such interaction leading to proteolytic cleavage of the
DPP4 protein. The binding energy of DPP4eKLK5 docking complex is
better than or comparable to (Supplementary Figure 4) that of few
randomly selected known protein complexes (Supplementary Table 1)
having similar sized interface area.
For the experimental validation of the modeling data in the cellular
context, we generated HepG2 cells stably expressing HA-tagged DPP4
(Supplementary Figure 5AeC) and treated them with recombinant
KLK5 enzyme. As shown in Figure 3D,E, KLK5 treated cells revealed a
w3 fold decrease in the surface expression of DPP4, as shown by1534 MOLECULAR METABOLISM 6 (2017) 1529e1539  2017The Authors. Published by Elsevier GmbH.confocal ﬂuorescence microscopy. Consistently, KLK5 treatment
inducedw5 fold increases in the release of soluble DPP4 in the media
(Figure 3F). Further, when KLK5 is overexpressed (Supplementary
Figure 5DeF) in these cells, we found a preferential decrease in the
surface expression of HA-tagged DPP4 from the KLK5 expressing cells
(Figure 3G,H). DPP4 expression was also low in the surrounding
untransfected cells, suggesting that KLK5 might cleave membrane
bound DPP4 predominantly by paracrine and autocrine fashion.
Expression of MMP2, another candidate protease, however, did not
induce DPP4 shedding in these cells (Supplementary Figure 5GeI).
Taken together, our data suggest that KLK5 cleaves DPP4 from the cell
surface by directly interacting with the extracellular loop.
3.5. CD4þ T cell derived KLK5 cleaves DPP4 from cell surface
Th1 and Th17 type CD4þ T cells signiﬁcantly contribute to the DPP4
levels in PBMC with Th17 cells showing higher DPP4 expression [17].This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Regulatory T cells (Treg), on the contrary, do not express DPP4 [34]. As
DPP4 shedding from PBMC in T2DM was higher, we wondered if
CD4þ T cells from T2DM patients would also share these charac-
teristics. When we stimulated PBMC with anti-CD3 and anti-CD28
antibodies for T cell receptor crosslinking, we found that the release
of DPP4 was increased in PBMC culture supernatants in T2DM
(Figure 4A) without any change in total cellular protein (Figure 4B).
Although DPP4 expression remained similar in the puriﬁed CD4þ T
cells (Figure 4C), KLK5 expression was signiﬁcantly enhanced in T2DM
(Figure 4D). However, secretion of both DPP4 (Figure 4E) and KLK5
(Figure 4F) from the puriﬁed CD4þ T cells was increased in T2DM
patients and was signiﬁcantly correlated (r ¼ 0.68, p  0.0001;
Figure 4G), suggesting that CD4þ T derived KLK5 could be responsible
for enhanced DPP4 shedding in T2DM. To further examine whether
CD4þ T cell derived KLK5 could cleave DPP4 from these cells, we
knocked down KLK5 in the CD4þ T cell from control subjects by
electroporating siRNA against KLK5 gene. Knockdown of KLK5 did not
alter DPP4 expression (Figure 4H) but signiﬁcantly reduced secretion ofFigure 4: Increased shedding of DPP4 from T cells of T2DM patients. (A, B) PBMC cu
(control n ¼ 9 & T2DM n ¼ 10). (CeD) Relative gene expression in CD4þ T cells for DP
Secreted DPP4 as well as KLK5 protein were measured by ELISA (control n ¼ 12 & T2DM
protein in overall population. (HeI) siKLK5 was electroporated in CD4þ T cells and gene e
CD4þ T cells were treated with human recombinant KLK5 (150 nM) for 4 h and culture s
cultured in a polylysine coated plate for 16 h, stained with DPP4 mAb (red) and visualized
was calculated of 100 different cells across four ﬁelds by Image J software. Data are show
Student’s t test with Spearman correlation; *p < 0.05, **p < 0.01, ***p < 0.001.
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treatment yielded enhanced release of DPP4 in the culture superna-
tants (Figure 4J) and decreased surface expression of DPP4 in CD4þ T
cells from healthy subjects (Figure 4K,L). Taken together, these results
thus reveal that CD4þ T cells from T2DM patients shed increased
amount of DPP4 through KLK5 dependent catalysis.
3.6. Shedding of DPP4 from Th17 cells is enhanced in T2DM
To investigate any preferential increase in the DPP4 expressing CD4þ
T cell subsets, we measured gene expressions of TBX21 and RORC,
the master regulator transcription factors driving Th1 and Th17 phe-
notypes of CD4þ T cells, respectively, and the percentage of Th1
(deﬁned by IFNgþCD4þ T cells) and Th17 (deﬁned by IL-17þCD4þ T
cells) cells in the PBMC by ﬂow cytometry. We did not detect any
difference either in gene expression (Supplementary Figure 6A, B) or in
the percentage of Th1 or Th17 cells of control and T2DM populations
(Supplementary Figure 6C, D). However, KLK5 expression was
signiﬁcantly higher in the puriﬁed Th17 cells (deﬁned bylture supernatants (A) and cell lysates (B) were analyzed for DPP4 by ELISA after 48 h
P4 and KLK5 in T2DM and control population (control n ¼ 18 & T2DM n ¼ 27). (EeF)
n ¼ 27). (G) Linear regression analysis of secreted DPP4 protein with secreted KLK5
xpression and secreted DPP4 levels were measured after 72 h (n ¼ 7). (J) Stimulated
upernatant was analyzed for DPP4 by ELISA (n ¼ 8). (K) Activated CD4þ T cells were
with ﬂuorescence confocal microscopy. Scale bar ¼ 10 mm. (L) Fluorescence intensity
n as the mean  SD. Statistical analysis was performed by ManneWhitney U test and
pen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1535
Original ArticleCCR6þCCR4þCD4þ T cells) from T2DM patients but not in the Th1
cells (deﬁned by CCR5þCXCR3þCD4þ T cells) (Figure 5A,B). Given
that PBMC derived DPP4 contributes to plasma DPP4 activity and that
shedding of DPP4 from CD4þ T cells could be one important mech-
anism in T2DM, we next sought to examine whether T helper cell
subsets contribute to plasma and PBMC DPP4 activity. We looked at
the correlations of plasma and PBMC DPP4 activity with the percent-
ages of IL-17þCD26þ T cells (Th17 cells) in circulation. Interestingly,
we found a signiﬁcant negative correlation with plasma DPP4 activity
and a positive association with PBMC DPP4 activity with fraction of
CD26þIL17þ subset within CD4þ T cells (although the later did not
reach statistical signiﬁcance; r ¼ 0.443, p ¼ 0.098) (Figure 5C,D). In
contrast, percentages IFNgþCD26þ T cells (Th1 cells) revealed a
signiﬁcant correlation with PBMC DPP4 activity but had no association
with plasma DPP4 activity (Figure 5E,F). Our ﬁndings thus suggested
that abundance of DPP4 activity in plasma of T2DM patients possibly
results from an enhanced shedding of soluble DPP4 proteins from the
Th17 cells. When we looked at surface expression of DPP4/CD26 on
these T helper cell subsets, we found no difference in the percentage
of IFNgþCD26þ T cells between control and T2DM (Figure 5G,H). In
contrast, we found a signiﬁcant decrease of the DPP4/CD26 surfaceFigure 5: Decreased surface expression of DPP4 in Th17 cells of T2DM patients. (A,
n ¼ 10 & T2DM, n ¼ 14). (C, D) Correlations of percentage of CD26þIL17AþCD4þ T ce
Correlations of percentage of CD26þIFNgþCD4þ T cells with plasma DPP4 activity (C; n ¼
CD26 staining (E) and the summary (F) of all the analyzed samples are shown (control n ¼
treatment naïve T2DM (n ¼ 19) were determined by ﬂow cytometry. Statistical analysis w
*p < 0.05, ***p < 0.001.
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These results thus conﬁrmed that rather than Th1 cells, Th17 cell-
derived DPP4 contributes to plasma DPP4 activity in T2DM.
4. DISCUSSION
DPP4 is ubiquitously expressed, but the sources of the soluble form of
plasma DPP4 in T2DM is not precisely known. In rodents, bone marrow
derived cells contribute 25e40% of plasma DPP4 [35,36] while liver
contributes signiﬁcantly to plasma DPP4 pool in human [37]. Although
immune cells contribute to the circulating DPP4 pool in mice, DPP4 in
endothelial cells is crucial for the inactivation of incretin hormones,
suggesting that an increase in circulatory DPP4 per se might not be
critical for incretin response and hence glycemic control [36]. Thus, the
physiological implications of immune cell derived DPP4 is still elusive
and moreover in humans the contribution of circulating immune cells in
sourcing plasma DPP4 speciﬁcally in the context of T2DM has not yet
been investigated. Here we show that increased plasma DPP4 activity
in T2DM patients is linked with the enhanced shedding of DPP4 from
circulating Th17 cells. Moreover, we identify KLK5 as the putative
protease that cleaves DPP4 from the CD4þ T cell surface. We alsoB) Comparison of relative KLK5 gene expression in sorted Th1 and Th17 cells (control,
lls with plasma DPP4 activity (A; n ¼ 26) and PBMC DPP4 activity (B; n ¼ 16). (E, F)
30) and PBMC DPP4 activity (D; n ¼ 15). (G, H) Representative ﬂow plots for IFNg and
17& T2DM n ¼ 12). (I, J) IL-17A and CD26 staining from healthy control (n ¼ 20) and
as performed by ManneWhitney U test and Student’s t test with Spearman correlation;
This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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found that Th17 cells in T2DM patients showed reduced surface
expression of DPP4/CD26, and the level of this reduction was positively
correlated with plasma DPP4 activity in the same patients. This study
thus provides data that deﬁne a major cellular source and mechanism
behind plasma DPP4 abundance in T2DM.
Consistent with the notion that T2DM patients usually do not exhibit
lowered GLP-1 secretion in response to glucose ingestion [38], we did
not ﬁnd any alteration in either basal or glucose induced surge in GLP-1
and GIP levels. In agreement with results from various population
groups [32,39], our data depict that plasma DPP4 activity is signiﬁcantly
increased in the Indian T2DM patients. However, mechanisms for the
increase in plasma DPP4 activity in T2DM have not yet been thoroughly
addressed. Obesity and associated metaﬂammation have been postu-
lated for this phenomenon, but, as the present cohort is comprised of
treatment naive, non-obese subjects, our data indicate that hypergly-
cemia alone could be responsible for increased plasma DPP4 activity.
It is becoming evident that an increase in pro-inﬂammatory Th1 and
Th17 subsets along with decrease in anti-inﬂammatory Treg cells are
associated with obesity and T2DM [40]. A predisposition toward Th17
cell response has been shown in obese women [41] and in diet-
induced obesity model in mice [42]. T cell inﬂammation in obesity-
associated T2DM patients has been characterized by elevated num-
ber of circulatory Th17 cells, increased Th17-derived cytokine pro-
duction, and activation of Th17 signature genes [41], which is
supported by the inﬂammatory milieu conferred by B cells [43]. Thus,
in addition to the detrimental role of Th17 in type 1 diabetes [44,45],
enhanced Th17-associated pro-inﬂammatory skewing in T2DM also
implicates Th17 cells as major players in the metaﬂammation asso-
ciated with T2DM. However, we did not ﬁnd any increase in the cir-
culatory Th17 cell number, either in the freshly isolated PBMC or
following CD4þ T cell culture and activation with anti-CD3/CD28
antibodies. These differences could be due to our non-obese, treat-
ment naïve cohort with shorter duration of disease.
Enhanced expression and secretion of CD4þ T cell-derived KLK5 in
T2DM is suggestive of a functional paracrine network that leads to
augmented DPP4 cleavage. Moreover, conspicuous presence of KLK5
transcript with a signiﬁcant positive association between secreted
KLK5 with shed DPP4 from CD4þ T cells further indicates that KLK5
can also work through an autocrine system. Enhanced expression of
KLK5 in Th17 cells from T2DM patients further demonstrate that cir-
culatory Th17 pool could be an important source of plasma DPP4.
KLK5 expression is induced by cytokines in neutrophils [46] and Th17
response is usually associated with neutrophil inﬁltration [47,48],
suggesting that neutrophils can also be another source of the protease
that leads to DPP4 shedding from the Th17 cells. Homing of circulatory
Th17 cells in tissues such as intestine, lung, and skin has been well
characterized [49], and, interestingly, KLK5 is maximally expressed in
skin [50]. Thus, skin being a site of KLK5 and Th17 cell interactions
can also be one of the possibilities. However, this warrants further
investigations.
Immune cell derived DPP4 contributes signiﬁcantly to plasma DPP4
pool [37]; thus, DPP4 expressed in immune cells represents a novel
target for various inﬂammatory diseases including T2DM [51]. Indeed,
DPP4 inhibitors such as sitagliptin exert an anti-inﬂammatory effect in
T2DM by reducing plasma inﬂammatory cytokine levels as well as
inﬂammatory gene expression in PBMC [52]. Interestingly, nonobese
patients of Asiatic origin respond better to gliptin therapy [53], which at
least partially could be implicated to T cell inﬂammation. Moreover, our
data on KLK5 mediated shedding of DPP4 opens up the possibility of
utilizing this interaction and catalysis for therapeutic targeting in
metaﬂammation and T2DM.MOLECULAR METABOLISM 6 (2017) 1529e1539  2017TheAuthors. Published by ElsevierGmbH. This is an o
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Collectively, our results show that in T2DM patients, circulating CD4þ T
cells, speciﬁcally cells having the Th17 phenotype, shed cleaved DPP4
protein into plasma due to the enzymatic action of KLK5. Expression and
secretion of KLK5 is enhanced in CD4þ T cells of T2DM patients. We
also gathered structural insights into the interaction of KLK5 with DPP4.
Thus, we uncovered a hitherto unknown link between T cell inﬂam-
mation and aberrant plasma DPP4 abundance in T2DM.
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